NVS
Novartis AG (NYSE: NVS) reported stronger-than-expected earnings and revenue as newer cancer treatments...
Article Summary
BUY- Novartis AG (NYSE: NVS) reported stronger-than-expected earnings and revenue as newer cancer treatments helped offset declining sales from its former blockbuster heart drug Entresto, with earnings excluding certain items beating expectations and sales returning to growth.
- Novartis AG ADR maintained full-year guidance for low-single-digit core operating profit declines and continued $15 billion in recent acquisitions, including Avidity Biosciences, Tourmaline Bio, and Synnovation Therapeutics.
- Rhapsido, Novartis AG ADR's new skin-disease pill launched in the US and China, generated $64 million in revenue, while R-Sylvia, a new treatment for chronic skin disease, posted $30 million in sales, beating expectations.
- Management reaffirmed its full year sales and operating-profit guidance, signaling confidence that the company is moving through the most difficult stage of its patent cliff.
- The stock rose as much as 3.
Free users see 3 BUY signals per day. Premium unlocks all of them, plus instant email alerts.
See Plans
Growth Stock Scoring Breakdown
| METRIC | VALUE | WEIGHT | ANALYSIS |
|---|---|---|---|
| Sales Growth TTM ? | 5.6% | 25% | 35.0 ptsBelow Screener (5.6%) - Weak growth |
| EPS Growth Next 5Y ? | 6.2% | 25% | 20.0 ptsWeak (6.2%) - Low expectations |
| Target Price Upside ? | 0.6% | 20% | 10.0 ptsNear/At Target (0.6%) - Target: $152.92 vs Current: $153.90 |
| Gross Margin % ? | 74.6% | 15% | 100.0 ptsExceptional (74.6%) - Strong pricing power |
| Drawdown from 52-Wk High ? | -9.7% | 15% | 20.0 ptsBarely a Dip (-9.7%) - Near recent highs |
Disclaimer: This rating is for informational purposes only and is not financial advice.
All data sourced from Finviz.
Always conduct your own research and consult with a financial advisor before making investment decisions.
Past performance does not guarantee future results.
About NVS
- Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally.
- The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD).
- It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still's disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta.
- The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology.
- It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol.
- Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.